AstraZeneca, and its global biologics research and development arm MedImmune, today announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company’s oncology portfolio and bringing new medicines to patients more quickly.
AstraZeneca will present new research spanning the Company’s Cardiovascular, Renal and Metabolism (CVRM) therapy area at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in San Diego, US, 23-28 October 2018.
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today announced detailed results from the Phase III SOLO-1 trial testing Lynparza (olaparib) tablets as a maintenance treatment for patients with newly-diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.
AstraZeneca today presented new data on the mechanisms of acquired resistance from the Tagrisso (osimertinib) pivotal Phase III FLAURA trial during an oral late-breaker abstract session at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich, Germany.
AstraZeneca today announced that the CHMP of the European Medicines Agency has adopted a positive opinion, recommending the marketing authorisation for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms inadult patients with chronic obstructive pulmonary disease (COPD).
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today announced that they were granted orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for Lynparza (olaparib) for the treatment of pancreatic cancer.
AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the European Society of Medical Oncology (ESMO 2018) Congress in Munich, Germany, 19-23 October.
AstraZeneca meddelar i dag att man har anställt Christina Malmberg Hägerstrand i en ny roll som presschef för bolaget i Norden och Baltikum. Hon börjar den 7 januari 2019 och kommer rapportera till Kommunikationsdirektör Jacob Lund.
Results from the Phase III PACIFIC trial were published simultaneously in the New England Journal of Medicine, showing Imfinzi (durvalumab) significantly improved OS, the second primary endpoint of the trial, compared to standard of care regardless of PD-L1 expression, reducing the risk of death by 32% (HR 0.68, 99.73% CI 0.47-0.997; p=0.0025).
Elisabeth Björk, Vice President, Head of Cardiovascular, Renal and Metabolic Diseases, at AstraZeneca said: “We are pleased with this positive recommendation for Bydureon and what it means for patients with type-2 diabetes with a wide range of cardiovascular risk. Our pursuit of this label is based on our strong belief in the clinical value the EXSCEL data brings to physicians and patients.”
AstraZeneca and MedImmune, today announced that the European Commission has granted marketing authorisation for Imfinzi (durvalumab) as monotherapy for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemotherapy and radiation therapy (CRT).
AstraZeneca meddelade i dag positiva övergripande resultat från den kardiovaskulära fas III-studien DECLARE-TIMI 58 for Forxiga (dapagliflozin), den bredaste kardiovaskulära studien hittills för en SGLT2-hämmare.
